| 1 |
Lourenço J, McNaughton AL, Pley C, Obolski U, Gupta S, Matthews PC. Polymorphisms predicting phylogeny in hepatitis B virus. Virus Evol 2023;9:veac116. [PMID: 36628296 DOI: 10.1093/ve/veac116] [Reference Citation Analysis]
|
| 2 |
Sarantis P, Trifylli E, Koustas E, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. IJMS 2022;23:13612. [DOI: 10.3390/ijms232113612] [Reference Citation Analysis]
|
| 3 |
Belaiba Z, Ayouni K, Gdoura M, Kammoun Rebai W, Touzi H, Sadraoui A, Hammemi W, Yacoubi L, Abdelati S, Hamzaoui L, Msaddak Azzouz M, Chouikha A, Triki H. Whole genome analysis of hepatitis B virus before and during long-term therapy in chronic infected patients: Molecular characterization, impact on treatment and liver disease progression. Front Microbiol 2022;13:1020147. [DOI: 10.3389/fmicb.2022.1020147] [Reference Citation Analysis]
|
| 4 |
Lourenço J, Mcnaughton AL, Pley C, Obolski U, Gupta S, Matthews PC. Polymorphisms Predicting Phylogeny in Hepatitis B Virus (HBV).. [DOI: 10.1101/2022.07.05.498824] [Reference Citation Analysis]
|
| 5 |
Sanaei N, Hashemi SMA, Dehno SZS, Asl MM, Moini M, Malek-Hosseini SA, Hosseini SY, Sarvari J. Precore/core mutations of hepatitis B virus genotype D arising in different states of infection. Clin Exp Hepatol 2022;8:21-8. [PMID: 35415256 DOI: 10.5114/ceh.2022.114253] [Reference Citation Analysis]
|
| 6 |
Wu J, Yu Y, Dai Y, Zhang Y, Cheng J, Cui D. Research Progress on the Mechanism of Persistent Low-Level HBsAg Expression in the Serum of Patients with Chronic HBV Infection. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/1372705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Marlet J, Lier C, Roch E, Moreau A, Combe B, Handala L, Lefeuvre S, Maugey M, Elkrief L, d'Alteroche L, Potier P, Brand D, Gaudy-Graffin C. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. Antiviral Res 2021;192:105106. [PMID: 34214504 DOI: 10.1016/j.antiviral.2021.105106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
